{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T06:34:07Z","timestamp":1773729247242,"version":"3.50.1"},"reference-count":39,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2020,9,6]],"date-time":"2020-09-06T00:00:00Z","timestamp":1599350400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/K015346\/1"],"award-info":[{"award-number":["MR\/K015346\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/N00583X\/1"],"award-info":[{"award-number":["MR\/N00583X\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012041","name":"Versus Arthritis","doi-asserted-by":"publisher","award":["21754"],"award-info":[{"award-number":["21754"]}],"id":[{"id":"10.13039\/501100012041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012041","name":"Versus Arthritis","doi-asserted-by":"publisher","award":["22072"],"award-info":[{"award-number":["22072"]}],"id":[{"id":"10.13039\/501100012041","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To determine whether using a reweighted disease activity score that better reflects joint synovitis, i.e., the 2\u2010component Disease Activity Score in 28 joints (<jats:styled-content style=\"fixed-case\">DAS<\/jats:styled-content>28) (based on swollen joint count and C\u2010reactive protein level), produces more clinically relevant treatment outcome trajectories compared to the standard 4\u2010component <jats:styled-content style=\"fixed-case\">DAS<\/jats:styled-content>28.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Latent class mixed modeling of response to biologic treatment was applied to 2,991 rheumatoid arthritis (<jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content>) patients in whom treatment with a biologic disease\u2010modifying antirheumatic drug was being initiated within the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort, using both 4\u2010component and 2\u2010component <jats:styled-content style=\"fixed-case\">DAS<\/jats:styled-content>28 scores as outcome measures. Patient groups with similar trajectories were compared in terms of pretreatment baseline characteristics (including disability and comorbidities) and follow\u2010up characteristics (including antidrug antibody events, adherence to treatments, and blood drug levels). We compared the trajectories obtained using the 4\u2010 and 2\u2010component scores to determine which characteristics were better captured by each.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Using the 4\u2010component <jats:styled-content style=\"fixed-case\">DAS<\/jats:styled-content>28, we identified 3 trajectory groups, which is consistent with previous findings. We showed that the 4\u2010component <jats:styled-content style=\"fixed-case\">DAS<\/jats:styled-content>28 captures information relating to depression. Using the 2\u2010component <jats:styled-content style=\"fixed-case\">DAS<\/jats:styled-content>28, 7 trajectory groups were identified; among them, distinct groups of nonresponders had a higher incidence of respiratory comorbidities and a higher proportion of antidrug antibody events. We also identified a group of patients for whom the 2\u2010component <jats:styled-content style=\"fixed-case\">DAS<\/jats:styled-content>28 scores remained relatively low; this group included a high percentage of patients who were nonadherent to treatment. This highlights the utility of both the 4\u2010 and 2\u2010component <jats:styled-content style=\"fixed-case\">DAS<\/jats:styled-content>28 for monitoring different components of disease activity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Here we show that the 2\u2010component modified <jats:styled-content style=\"fixed-case\">DAS<\/jats:styled-content>28 defines important biologic and clinical phenotypes associated with treatment outcome in <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> and characterizes important underlying response mechanisms to biologic drugs.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.41379","type":"journal-article","created":{"date-parts":[[2020,5,31]],"date-time":"2020-05-31T12:25:53Z","timestamp":1590927953000},"page":"1632-1642","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Latent Class Trajectory Modeling of 2\u2010Component Disease Activity Score in 28 Joints Identifies Multiple Rheumatoid Arthritis Phenotypes of Response to Biologic Disease\u2010Modifying Antirheumatic Drugs"],"prefix":"10.1002","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5041-0409","authenticated-orcid":false,"given":"Arianna","family":"Dagliati","sequence":"first","affiliation":[{"name":"Centre for Health Informatics and Manchester Molecular Pathology Innovation Centre University of Manchester  Manchester UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darren","family":"Plant","sequence":"additional","affiliation":[{"name":"Versus Arthritis Centre for Genetics and Genomics University of Manchester NIHR Manchester Biomedical Research Centre Manchester University NHS Foundation Trust, and Manchester Academic Health Science Centre  Manchester UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nisha","family":"Nair","sequence":"additional","affiliation":[{"name":"Versus Arthritis Centre for Genetics and Genomics University of Manchester  Manchester UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1487-277X","authenticated-orcid":false,"given":"Meghna","family":"Jani","sequence":"additional","affiliation":[{"name":"Versus Arthritis Centre for Epidemiology University of Manchester  Manchester UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Amico","sequence":"additional","affiliation":[{"name":"University of Verona  Verona Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels","family":"Peek","sequence":"additional","affiliation":[{"name":"Centre for Health Informatics University of Manchester NIHR Manchester Biomedical Research Centre Manchester University NHS Foundation Trust, and Manchester Academic Health Science Centre  Manchester UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann W.","family":"Morgan","sequence":"additional","affiliation":[{"name":"University of Leeds School of Medicine NIHR Leeds Biomedical Research Centre, and Leeds Teaching Hospitals NHS Trust  Leeds UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Isaacs","sequence":"additional","affiliation":[{"name":"Translational and Clinical Research Institute Newcastle University, and Newcastle upon Tyne Hospitals NHS Foundation Trust  Newcastle upon Tyne UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4855-3926","authenticated-orcid":false,"given":"Anthony G.","family":"Wilson","sequence":"additional","affiliation":[{"name":"Centre for Arthritis Research Conway Institute University College Dublin  Dublin Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimme L.","family":"Hyrich","sequence":"additional","affiliation":[{"name":"NIHR Manchester Biomedical Research Centre Manchester University NHS Foundation Trust Manchester Academic Health Science Centre, and Versus Arthritis Centre for Epidemiology University of Manchester  Manchester UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nophar","family":"Geifman","sequence":"additional","affiliation":[{"name":"Centre for Health Informatics and Manchester Molecular Pathology Innovation Centre University of Manchester  Manchester UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Barton","sequence":"additional","affiliation":[{"name":"Versus Arthritis Centre for Genetics and Genomics University of Manchester NIHR Manchester Biomedical Research Centre Manchester University NHS Foundation Trust, and Manchester Academic Health Science Centre  Manchester UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the BRAGGSS Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,9,6]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-22578-1"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5022"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6947-14-24"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-016-1116-1"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000000602"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/jamia\/ocv213"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aao3612"},{"key":"e_1_2_6_9_1","first-page":"176","article-title":"Patient stratification using longitudinal data: application of latent class mixed models","volume":"247","author":"Geifman N","year":"2018","journal-title":"Stud Health Technol Inform"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-017-0332-0"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001602"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwx188"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1198\/016214502753479220"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12858"},{"key":"e_1_2_6_15_1","first-page":"ii185","article-title":"Identifying subgroups of renal function trajectories","volume":"32","author":"Boucquemont J","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517703800"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0135327"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket253"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380107"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22175"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2016.08.024"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000721"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez049"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208849"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39169"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22249"},{"key":"e_1_2_6_27_1","unstructured":"DAS 28. URL:https:\/\/www.das-score.nl\/das28\/\u200ben\/."},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780230202"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.2196\/jmir.9134"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/jamia\/ocx071"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/1932296817706375"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-11-15"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v078.i02"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-020683"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v069.i01"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2018.1465409"},{"key":"e_1_2_6_37_1","first-page":"478","article-title":"Body mass index and response to infliximab in rheumatoid arthritis","volume":"33","author":"Ottaviani S","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390105"},{"key":"e_1_2_6_39_1","unstructured":"National Institute for Health and Care Excellence.Drug treatment for rheumatoid arthritis. URL:https:\/\/pathw\u200bays.nice.org.uk\/pathw\u200bays\/rheum\u200batoid-arthr\u200bitis#path=view%3A\/pathw\u200bays\/rheum\u200batoid-arthr\u200bitis\/drug-treat\u200bment-for-rheum\u200batoid-arthr\u200bitis.xml&conte\u200bnt=view-index."},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-016-1319-x"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.41379","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.41379","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/art.41379","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.41379","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T11:31:21Z","timestamp":1759923081000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.41379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,6]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.1002\/art.41379"],"URL":"https:\/\/doi.org\/10.1002\/art.41379","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,6]]},"assertion":[{"value":"2020-01-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}